Taken together, these results highlight TMEM16A not only as a potential biomarker for prostate cancer but also as a promising target for therapeutic strategies, setting the stage for the advancement of targeted treatments that may greatly influence patient management and outcomes. This evidence concerns the gene ANO1 and prostate carcinoma.